Jazz Pharmaceuticals (JAZZ) +11.2% AH after agreeing to acquire privately-held EUSA Pharma for...

|About: Jazz Pharmaceuticals, Inc. (JAZZ)|By:, SA News Editor

Jazz Pharmaceuticals (JAZZ) +11.2% AH after agreeing to acquire privately-held EUSA Pharma for as much as $700M in cash. EUSA's FDA-approved Erwinaze treatment blocks cell growth in patients with acute leukemia by cutting down asparagine levels in the bloodstream. Jazz expects the deal to add $210M-$230M in revenue and $0.75-$0.85/share in earnings.